,116,117 Notably, doxorubicin can induce immunogenic cell death in tumor cells, promoting the release of damage-associated molecular patterns, which, in turn, can facilitate the priming of tumor-specific CD8+ T cells and activate STING pathway.118. The gene discussed is STING1; the disease is neoplasm.